Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FPRX Five Prime Therapeutics (FPRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Five Prime Therapeutics Stock (NASDAQ:FPRX) 30 days 90 days 365 days Advanced Chart Remove Ads Get FPRX alerts:Sign Up Key Stats Today's Range$38.00▼$38.0050-Day Range$37.65▼$38.0052-Week Range$2.61▼$38.90VolumeN/AAverage Volume1.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More… Remove Ads Receive FPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FPRX Stock News HeadlinesInterim award has Prime Therapeutics paying more than $10 million to California-based pharmacyFebruary 3, 2025 | startribune.comPlay Five Card Draw Online for Free | Yahoo! GamesAugust 9, 2024 | yahoo.com[OPEN NOW] New rules to trade options with.Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!March 31, 2025 | WealthPress (Ad)CMMB Chemomab Therapeutics Ltd.March 28, 2024 | seekingalpha.com33+ best October Prime Day deals you can still shop right nowOctober 15, 2023 | nbcnews.comNK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)October 11, 2023 | benzinga.comThe Giants’ prime time TV demons are haunting them nowOctober 3, 2023 | nypost.comWhat Is The Prime Rate Today?August 3, 2023 | forbes.comSee More Headlines FPRX Stock Analysis - Frequently Asked Questions How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company earned $2.05 million during the quarter, compared to analysts' expectations of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%. Read the conference call transcript. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/06/2020Today3/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FPRX CIK1175505 Webwww.fiveprime.com Phone415-365-5600FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,200,000.00 Net Margins-554.71% Pretax MarginN/A Return on Equity-75.84% Return on Assets-49.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$14.87 million Price / Sales119.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book9.20Miscellaneous Outstanding Shares46,572,000Free FloatN/AMarket Cap$1.77 billion OptionableOptionable Beta4.40 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:FPRX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Five Prime Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Five Prime Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.